Meeting
2023 ASCO Gastrointestinal Cancers Symposium
First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
Authors
James J. Harding
Memorial Sloan Kettering Cancer Center, New York, NY;
James J. Harding , Cesar Augusto Perez , Shumei Kato , Manish Sharma , Benjamin Garmezy , Cheng Seok Quah , Betty Tam , Paul Severson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05242822
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS637)
DOI
10.1200/JCO.2023.41.4_suppl.TPS637
Abstract #
TPS637
Poster Bd #
P6
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Design and rationale of a first-in-human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible (irrev), pan-FGFR inhibitor (FGFRi), in adult patients with solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822).
First Author: Lipika Goyal
Poster
2023 ASCO Genitourinary Cancers Symposium
First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced urothelial carcinoma (UC) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
First Author: Benjamin Garmezy
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-308: Phase III study of tinengotinib versus physician's choice in patients with FGFR-altered, chemotherapy- and FGFR inhibitor–refractory/relapsed cholangiocarcinoma.
First Author: Milind M. Javle
Poster
2021 ASCO Annual Meeting
Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations.
First Author: Ye Guo